Figure 3.

Schematic illustration of the main studies involving new types of PS for application in cancer PDT. (A) Synthesis of the FASOC-UCNP-ZnPc nanoconstruct and folate-mediated binding of tumor cells with folate receptor expression. Comparison of the therapeutic efficacy of deep tissue PDT triggered by 980 and 660-nm light. (A) Tumor growth of mice in different treatment groups within 15 days. Adapted from [51]. Reproduced with permission from the American Chemical Society, Copyright © 2013. (B) Construction of the MH-PLGA-IR780 NPs and the specific killing mechanism of the targeted theranostic nanoplatform-mediated PDT approach. The tumor volume was measured during the therapeutic period. (The data are presented as the mean ± SD values; n = 5, * p < 0.05, and ** p < 0.01.) Adapted from [58]. Reproduced with permission from Springer Nature, Copyright © 2022. (C) Targeted PDT on a Hela tumor-bearing mouse intravenously injected with FA-NMe2Se4N2 NPs. Change of relative tumor volume (V/V0) after mice were intravenously injected with PBS, NMe2Se4N2 NPs, or FA-NMe2Se4N2 NPs and irradiated with a 808-nm laser at 100 mV cm⁻² for 30 min. Data are the means ± SD (6 mice per group), *** p < 0.001 compared to other groups using a one-way ANOVA. Adapted from [57]. Reproduced with permission from the American Chemical Society, Copyright © 2013.